Nuclera breaks into Asia through Taiwan university deals as it scales globally
CEO and co-founder Michael Chen says the successes mark a major milestone in Nuclera's global expansion blueprint.
Its systems are now operational at the Department of Pharmacy and the Department of Chemistry at the National Taiwan University (NTU) College of Medicine and the Center for Bioscience and Biotechnology and Department of Chemical Engineering at the National Cheng Kung University (NCKU).
Following the installation of eProtein Discovery at leading academic institutes across the UK and Europe, the expansion into Taiwan further underscores the company’s accelerating global adoption and its growing role in enabling next-generation protein research worldwide.
The eProtein Discovery Systems were bought by Show Chung Ho, President of YFY Academy and Founder of E Ink Holdings, and donated to support the capabilities of NTU and NCKU to facilitate continued research in protein drug development. The two universities will form a collaborative platform focused on protein drug discovery, ensuring Taiwan remains aligned with international progress in this rapidly advancing field.
Michael Chen says: “eProtein Discovery is transforming protein production workflows through rapidly informing scientists of optimal protein expression and purification conditions. We are excited to play a role in the important research that is being carried out at the National Taiwan University and the National Cheng Kung University. These first Asian installations represent an important moment for Nuclera, strengthening our global footprint and demonstrating the growing worldwide demand for rapid access to functional proteins.”
Show Chung Ho added: “At E Ink and YFY, we are thrilled to have been able to support these Universities with accessing Nuclera’s powerful System. Having access to eProtein Discovery will enable these institutions to streamline protein synthesis, paving the way for pioneering research in new protein drug development. This collaboration creates a valuable platform that positions Taiwan at the forefront of international progress in protein research.”
Combining unique cell-free expression systems, novel digital microfluidics and robust screening data, eProtein Discovery provides clear guidance on which protein has the best chance of success early on, reducing the time, cost, and uncertainty traditionally associated with protein expression and purification.
Nuclera is represented in Taiwan by Unimed Healthcare Inc., which is responsible for local distribution and technical support. Founded in 2013, Nuclera has transatlantic operations in Cambridge UK and Boston in the US.
Nuclera was named leading biotech in the cluster at September's Business Weekly Awards presentation in September for the second successive year as AstraZeneca's UK chairman Shaun Grady handed out the accolades.